Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06319898 · ClinicalTrials.gov registry record · NA

Relaxing Environment to Lower Anxiety During Onabotulinum Toxin Chemodenervation of the Bladder

A NA study, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
NA
Development phase
113
Enrollment target

NCT06319898: Completed NA study, sponsored by Wake Forest University Health Sciences.

NCT06319898 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 113 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06319898, a NA study, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
NA
Development phase
113 participants
Enrollment target

Study Summary

Chemodenervation of the bladder with onabotulinum toxin A is an effective treatment option for patients with refractory urgency urinary incontinence (UUI). It is often performed as an office-based procedure under local anesthesia. Alternatively, it can be performed in the operating room under general anesthesia. The ability to receive intra-detrusor chemodenervation in the office allows patients to avoid the risks associated with general anesthesia and is significantly more cost effective. The procedure, however, is painful and can be anxiety provoking for patients; especially given that patients typically return every six to nine months for repeat injections. Relaxation and distraction techniques are one way to ease patients' anxiety before an office-based procedure. While we do not know exactly how anxiety provoking office bladder chemodenervation is for patients, we do know that anxiety disorders are highly prevalent in women with overactive bladder as a population. The purpose of this study is to investigate whether women with Urge urinary incontinence (UUI) who receive office intra-detrusor chemodenervation injections performed in a relaxing environment of lavender aromatherapy, calming music, dim lighting, and modest positioning (Relaxing Environment Package) will have decreased anxiety and pain as well as increased post-procedure satisfaction compared to patients who receive chemodenervation in a typical office environment. Also investigate whether exposure to the relaxing environment impacts the well-being of staff involved in these procedures. This study design is a randomized control trial. Women scheduled for office intra-detrusor chemodenervation at Atrium Health women's Care Urogynecology \& Pelvic Surgery - Mercy clinic will be invited to participate. Participants will be randomized to the relaxing environment package or the placebo group after informed consent is obtained and immediately before undergoing intra-detrusor chemodenervation. The particip

Primary Outcome

The VAS for anxiety is a validated scale that ranges from 0-100mm. 0mm is equivalent to "no anxiety" and is located on the left. 100mm is equivalent to "extremely anxious" and is located on the right. The minimum clinically important difference for VAS anxiety is a change of 12mm on a 100mm scale.

Interventions

  • BEHAVIORAL Lavender aromatherapy sticker

Trial Details

FieldValue
Enrollment Target 113 participants
Start Date 2024-05-22
Est. Completion 2024-08-12
Phase NA
Wake Forest University Health Sciences

1,140 total trials

What the finished NCT06319898 record still lists

NCT06319898 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 1 intervention - of which Lavender aromatherapy sticker is the first listed.

NCT06319898 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06319898 about?

NCT06319898 is a clinical study titled "Relaxing Environment to Lower Anxiety During Onabotulinum Toxin Chemodenervation of the Bladder". Chemodenervation of the bladder with onabotulinum toxin A is an effective treatment option for patients with refractory urgency urinary incontinence (UUI). It is often performed as an office-based procedure under local anesthesia. Alternatively, it can be performed in the operating room under genera...

What is the current status of trial NCT06319898?

This trial is currently completed. It is a NA study. The enrollment target is 113 participants. The study started on 2024-05-22. Estimated completion is 2024-08-12.

What interventions are being tested in trial NCT06319898?

The interventions under investigation include: Lavender aromatherapy sticker (BEHAVIORAL).

Who is sponsoring clinical trial NCT06319898?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06319898's enrollment target sits among peer trials

113 813th of 2000 higher than 1,188 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00748254 · 113 participants

    Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis

  • NCT04753190 · 113 participants · NA

    Light Timing Study

  • NCT05799248 · 113 participants · Phase 3

    Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

  • NCT07216105 · 113 participants · Phase 1

    FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06319898, the US trial registry maintained by the National Library of Medicine. NCT06319898 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.